{"id":"conditioning-regimen","safety":{"commonSideEffects":[{"rate":"50-90%","effect":"Nausea and vomiting"},{"rate":"30-70%","effect":"Fatigue"},{"rate":"20-60%","effect":"Hair loss"},{"rate":"10-50%","effect":"Diarrhea"},{"rate":"10-40%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The regimen typically includes high-dose chemotherapy and total body irradiation to eliminate cancer cells and suppress the immune system, making it possible for the new bone marrow to engraft and produce healthy blood cells.","oneSentence":"This conditioning regimen involves a combination of chemotherapy and radiation therapy to prepare the body for a bone marrow transplant.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:28:17.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Preparation for bone marrow transplant in patients with hematological malignancies"}]},"trialDetails":[{"nctId":"NCT02116764","phase":"","title":"Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-06-11","conditions":"Chronic Granulomatous Disease","enrollment":137},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT01659606","phase":"PHASE2","title":"Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2012-07","conditions":"Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome","enrollment":40},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT06060613","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Obsidian Therapeutics, Inc.","startDate":"2023-10-25","conditions":"Tumor Skin, Metastatic Melanoma, Melanoma","enrollment":208},{"nctId":"NCT06209190","phase":"NA","title":"Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-09-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":14},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy","enrollment":9},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT07490054","phase":"PHASE1","title":"Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure","status":"RECRUITING","sponsor":"Melana Yuzefpolskaya, MD","startDate":"2025-09-01","conditions":"Chronic Heart Failure","enrollment":40},{"nctId":"NCT06150651","phase":"PHASE1","title":"Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-01","conditions":"SLE (Systemic Lupus)","enrollment":3},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT04103879","phase":"PHASE2","title":"US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2020-11-13","conditions":"High Risk Hematological Malignancy, Cord Blood Transplant","enrollment":30},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06658951","phase":"NA","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"UTC Therapeutics Inc.","startDate":"2025-04-03","conditions":"HER2-positive Advanced Malignant Solid Tumors","enrollment":30},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT07481669","phase":"PHASE2","title":"ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Lymphoma Patients With High-risk of Central Nervous System Relapse","enrollment":45},{"nctId":"NCT07479797","phase":"PHASE3","title":"Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-08","conditions":"Relapsed or Refractory Large B-cell Lymphoma (r/r LBCL)","enrollment":550},{"nctId":"NCT03441958","phase":"PHASE1, PHASE2","title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-03-07","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT07480928","phase":"PHASE1, PHASE2","title":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease","enrollment":42},{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT05436561","phase":"PHASE2","title":"Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2022-06-01","conditions":"Disease-free Survival","enrollment":61},{"nctId":"NCT05478837","phase":"PHASE1","title":"Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-07-20","conditions":"Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":12},{"nctId":"NCT06481735","phase":"PHASE1, PHASE2","title":"TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-02-15","conditions":"Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT03392987","phase":"PHASE2","title":"A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)","status":"COMPLETED","sponsor":"Orchard Therapeutics","startDate":"2018-01-25","conditions":"Lysosomal Storage Disease, Metachromatic Leukodystrophy","enrollment":10},{"nctId":"NCT07473167","phase":"PHASE1, PHASE2","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","status":"RECRUITING","sponsor":"TICAROS Co., Ltd.","startDate":"2023-08-03","conditions":"Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":98},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT04960579","phase":"PHASE1","title":"P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma","status":"RECRUITING","sponsor":"Poseida Therapeutics, Inc.","startDate":"2022-05-05","conditions":"Multiple Myeloma","enrollment":275},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT05022849","phase":"PHASE1","title":"A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT05767359","phase":"PHASE2","title":"CAR- PRISM (PRecision Intervention Smoldering Myeloma)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-04-19","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma","enrollment":20},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT04819841","phase":"PHASE1, PHASE2","title":"Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease","status":"RECRUITING","sponsor":"Kamau Therapeutics","startDate":"2021-11-15","conditions":"Sickle Cell Disease","enrollment":15},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT07372885","phase":"PHASE1, PHASE2","title":"GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia","status":"NOT_YET_RECRUITING","sponsor":"University of Manchester","startDate":"2026-02-09","conditions":"Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic","enrollment":50},{"nctId":"NCT03587272","phase":"PHASE2","title":"Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Robert Nickel","startDate":"2018-04-17","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT02629120","phase":"PHASE1, PHASE2","title":"High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-17","conditions":"Chronic Granulomatous Disease Transplant","enrollment":45},{"nctId":"NCT07275736","phase":"EARLY_PHASE1","title":"A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2025-03-01","conditions":"Neurological Autoimmune Diseases","enrollment":18},{"nctId":"NCT03249831","phase":"PHASE1","title":"A Blood Stem Cell Transplant for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-04","conditions":"Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies","enrollment":3},{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187},{"nctId":"NCT02333162","phase":"PHASE1","title":"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2014-12-05","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT06138132","phase":"PHASE1","title":"A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-04-10","conditions":"Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive","enrollment":12},{"nctId":"NCT06014762","phase":"PHASE1","title":"P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies","status":"RECRUITING","sponsor":"Poseida Therapeutics, Inc.","startDate":"2024-04-16","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)","enrollment":120},{"nctId":"NCT05639972","phase":"PHASE1, PHASE2","title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","status":"RECRUITING","sponsor":"Christian Hinrichs","startDate":"2025-08-11","conditions":"HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy","enrollment":15},{"nctId":"NCT05686226","phase":"PHASE2","title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","status":"RECRUITING","sponsor":"Christian Hinrichs","startDate":"2023-03-07","conditions":"Cervical Cancer, Throat Cancer, Oropharynx Cancer","enrollment":20},{"nctId":"NCT03617185","phase":"NA","title":"Effect of Exercise and Surgical Weight Loss on Polyneuropathy","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-07-27","conditions":"Polyneuropathies, Obesity, Bariatric Surgery Candidate","enrollment":140},{"nctId":"NCT03850366","phase":"PHASE2","title":"HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2016-03-08","conditions":"Hematological Malignancy","enrollment":15},{"nctId":"NCT05589896","phase":"PHASE1, PHASE2","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Ossium Health, Inc.","startDate":"2024-08-16","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT05170828","phase":"PHASE1","title":"Cryopreserved MMUD BM With PTCy for Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Ossium Health, Inc.","startDate":"2022-09","conditions":"Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT05432635","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":15},{"nctId":"NCT07216443","phase":"PHASE2","title":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2025-12-09","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia","enrollment":80},{"nctId":"NCT07284641","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2026-03-01","conditions":"Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation","enrollment":25},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT03480360","phase":"PHASE3","title":"Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2018-03-28","conditions":"Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia","enrollment":21},{"nctId":"NCT00544466","phase":"PHASE1, PHASE2","title":"Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-31","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":75},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT03619551","phase":"PHASE2","title":"Conditioning SCID Infants Diagnosed Early","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2018-10-22","conditions":"SCID","enrollment":56},{"nctId":"NCT04761770","phase":"PHASE2","title":"Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-15","conditions":"Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia","enrollment":33},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT07104799","phase":"PHASE1","title":"Momelotinib During and After HCT in Myelofibrosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-01","conditions":"Myelofibrosis, Hematopoietic Cell Transplantation (HCT)","enrollment":28},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT02844361","phase":"PHASE4","title":"Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":70},{"nctId":"NCT05654779","phase":"PHASE1","title":"CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-12","conditions":"Acute Myeloid Leukemia","enrollment":4},{"nctId":"NCT07400328","phase":"PHASE2","title":"Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Oral Mucositis, Stomatitis, Gastrointestinal Mucositis","enrollment":22},{"nctId":"NCT04806347","phase":"PHASE1","title":"Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Blood Disease","enrollment":12},{"nctId":"NCT04803006","phase":"PHASE2","title":"A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2023-01-17","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT06197178","phase":"PHASE1","title":"A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)","status":"TERMINATED","sponsor":"Peking University","startDate":"2023-12-28","conditions":"Advanced Gastrointestinal Tumors","enrollment":17},{"nctId":"NCT06001385","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2023-12-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia","enrollment":313},{"nctId":"NCT06115486","phase":"NA","title":"EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer","status":"RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2024-01-09","conditions":"Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Female","enrollment":30},{"nctId":"NCT07023887","phase":"","title":"Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning","status":"RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2025-05-21","conditions":"Cancer, Breast Cancer","enrollment":15},{"nctId":"NCT07331272","phase":"PHASE1","title":"A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)","status":"RECRUITING","sponsor":"Nanjing Legend Biotech Co.","startDate":"2026-01-29","conditions":"Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)","enrollment":38},{"nctId":"NCT06028828","phase":"PHASE2","title":"Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2023-09-11","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies","enrollment":60},{"nctId":"NCT06193889","phase":"PHASE2, PHASE3","title":"KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2024-08-28","conditions":"Myasthenia Gravis, Generalized Myasthenia Gravis","enrollment":66},{"nctId":"NCT05917405","phase":"PHASE2","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-09-14","conditions":"Acute Myeloid Leukemia in Remission","enrollment":302},{"nctId":"NCT07011004","phase":"PHASE1","title":"A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT04262843","phase":"PHASE2","title":"Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-02-07","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT04784052","phase":"PHASE1, PHASE2","title":"Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab","status":"RECRUITING","sponsor":"Porteus, Matthew, MD","startDate":"2021-12-07","conditions":"Fanconi Anemia","enrollment":18},{"nctId":"NCT03121001","phase":"PHASE2","title":"Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-03-20","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT04196413","phase":"PHASE1","title":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-06-04","conditions":"Glioma of Spinal Cord, Glioma of Brainstem","enrollment":97},{"nctId":"NCT06464965","phase":"PHASE1","title":"Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-07-03","conditions":"Gastric Cancer, Pancreas Adenocarcinoma","enrollment":10},{"nctId":"NCT06710769","phase":"NA","title":"Ovarian Tissue Cryopreservation","status":"RECRUITING","sponsor":"Phoenix Children's Hospital","startDate":"2020-07-30","conditions":"Infertility, Female","enrollment":40},{"nctId":"NCT07358195","phase":"EARLY_PHASE1","title":"Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-07","conditions":"Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5811,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Endoxan","Antithymocyte globulin (ATG) rabbit : Thymoglobulin","Antithymocyte globulin (ATG) horse : Atgam","nonmyeloablative preparative regimen"],"phase":"phase_2","status":"active","brandName":"Conditioning regimen","genericName":"Conditioning regimen","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This conditioning regimen involves a combination of chemotherapy and radiation therapy to prepare the body for a bone marrow transplant. Used for Preparation for bone marrow transplant in patients with hematological malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}